The Multiple Sclerosis Treatment Optimization Program-Reference-Cited by-同舟云学术

The Multiple Sclerosis Treatment Optimization Program

Published:2021-10-18 Issue:11 Volume:8 Page:2146-2154
ISSN:2328-9503
Container-title:Annals of Clinical and Translational Neurology
language:en
Short-container-title:Ann. Clin. Transl. Neurol.

Author:

Langer‐Gould Annette¹^ORCID,Cheng Stephen C.²,Li Bonnie H.³,Kanter Michael H.⁴

Affiliation:

1. Department of Neurology Los Angeles Medical Center Southern California Permanente Medical Group Los Angeles CaliforniaUSA

2. Kaiser Foundation Health Plan Drug Use Management Downey CaliforniaUSA

3. Department of Research & Evaluation Southern California Permanente Medical Group Pasadena CaliforniaUSA

4. Department of Clinical Science Bernard J. Tyson School of Medicine Pasadena CaliforniaUSA

Publisher

Wiley

Subject

Clinical Neurology,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acn3.51472

Reference17 articles.

1. Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D

2. Institute for Clinical and Economic Review (ICER).Disease‐modifying therapies for relapsing‐remitting and primary progressive multiple sclerosis: effectiveness and value. Final Evidence Report. March 6 2017. Accessed September 01 2020.http://icerorg.wpengine.com/wp‐content/uploads/2020/10/CTAF_MS_Final_Report_030617.pdf

3. Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60

4. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes

5. Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Neurologist’s Guide to Drug Pricing in the United States;CONTINUUM: Lifelong Learning in Neurology;2024-08

2. The Role of Clinical Pharmacists in Patient-Centric Comprehensive Multiple Sclerosis Care;International Journal of MS Care;2024-01-01

3. Impact of a specific consultation for patients with progressive forms of multiple sclerosis on the response to their unmet care needs: a cross-sectional study;Multiple Sclerosis and Related Disorders;2023-04

4. Should Rituximab Be Considered for Relapsing Forms of MS?;Neurology Today;2022-12-15

5. Better Patient Outcomes at Less Cost: An Effective Strategy for Neurology Care;Annals of Neurology;2022-06-11